CareDx to present 30+ abstracts at 2026 American Transplant Congress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress
June 18, 2026 7:05 AM EDTGrowing body of evidence supports AlloSure® as a clinical endpoint for risk assessment, treatment response, and long-term graft outcomes
Data across kidney, heart, lung, and multi-organ transplantation; featuring new KOAR prognostic findings and ImmuneScape single cell and spatial transcriptomics rejection classification advances
BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) The Transplant Company, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, highvalue healthcare solutions for transplant patients and caregivers, today announced its participation at the American Transplant Congress (ATC) 2026, taking place June 2024 in... More
